Alunib 90mg Tablet is a targeted therapy addressing the unique needs of NSCLC patients with specific genetic mutations driving cancer growth.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Treat a certain type of non-small cell lung cancer (NSCLC)
Tyrosine Kinase Inhibitor (TKI):
Inhibition of ALK Signaling:
Antitumor Activity:
Activity Against ALK-Driven Tumors:
Brigatinib's ability to inhibit key signaling pathways and its antitumor activity against various mutations, especially in the context of ALK-driven tumors, highlights its potential as a targeted therapy for certain types of cancer, particularly non-small cell lung cancer. These findings suggest a promising role for Brigatinib in the treatment of patients who have developed resistance to previous therapies, such as crizotinib.
Alunib 90 is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic Non-Small Cell Lung Cancer (NSCLC) who have progressed on or are intolerant to Crizotinib.
Hypersensitivity to Brigatinib or any components.
Keep below 30°C, away from light & moisture. Keep out of the reach of children.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.